We are Breast Cancer Now, the UK’s leading breast cancer research charity. We believe research is what will ultimately give women with breast cancer more time to live. Our ambition: by the year 2050, everyone who develops breast cancer will live and will be supported to live well.
To get ahead of this complex disease, we need to change how we work. The big discoveries and the blockbuster drugs aren’t how we’ll move forward. It will be the incremental discoveries applied in different ways that will lead to truly targeted treatments. It will involve the academic research sector, pharmaceutical industry and charities like Breast Cancer Now working together.
To drive this, we have established a funding initiative called the Breast Cancer Now Catalyst Programme. This initiative will bring together Europe’s leading breast cancer researchers and the world’s leading pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050.
The first partnership we’ve made is with Pfizer. Together we will provide exciting opportunities for breast cancer researchers across Europe.
As well as providing substantial funding for research grants, Pfizer is providing access to a number of its licensed and investigational drugs that may be useful for treating breast cancer.
Breast Cancer Now will use its peer review process to decide which research projects will be supported and will have access to Pfizer’s drugs. Pfizer will not be involved in making the decisions about which projects are funded.
The request for proposals
We are looking for innovative proposals from researchers who are interested in using drugs from Pfizer listed here (opens as PDF). We are particularly interested in funding clinical research but would welcome preclinical research proposals, using the drugs alone or in combination with other agents.
The scope of the scheme
We are interested in funding single clinical research projects or more substantial research programmes that address problems in breast cancer and involve the use of drugs available from Pfizer.
This could include:
- Early phase clinical studies (Phase I/II)
- Clinical studies of the drugs in combination with other drugs (including those from other companies) or other treatment modalities.
We will also consider preclinical research proposals including:
- Pre-clinical research investigating the mechanisms of action of the drugs
- Pre-clinical research that could lead to repurposing existing drugs, including new indications for already licensed drugs
- Research to develop and test biomarkers or diagnostics to be used with the drugs.
This list is not intended to be exhaustive. Breast Cancer Now would be interested to hear of any proposals that make use of Pfizer’s drugs, so please contact the office if you would like to discuss your ideas.
Please note that the following areas of research will not be covered by this scheme:
- Phase III registration studies
- Research that is not primarily directed at investigations using one of the Pfizer drugs
- Proposals solely based on health economics
The Catalyst Grants cannot be used to support research leading directly to (i) regulatory approval of a new indication for a drug, or (ii) any significant change in the drug’s current labelling, or (iii) a change in the advertising for the drug.
The funding available
The nature and scope of the proposed research will vary from application to application, therefore we expect that the size and duration of each awarded grant will also vary.
However, grants should fit one of these broad categories:
- Grants of up to £400,000 in total. These are likely to address a single research question and may be based at one or multiple sites in the UK or Europe.
- Large grants of up to £1.5 million in total for studies of exceptional potential. These will likely involve teams across more than one site, including teams in institutions outside Europe. They may address a range of questions around a common theme, or undertake research using several of the Pfizer drugs, or multi-centre phase II clinical studies.
Larger amounts will be considered with appropriate justification, particularly where substantial sample collection and/or biomarker investigation is included.
Please note these grants will not be renewable once they have ended.
Expression of Interest
Applications are now closed for Expressions of Interest.
Expressions of interest will initially be assessed for eligibility and then reviewed by the Catalyst Grant Committee, which will include researchers with experience in pre-clinical and clinical drug development, as well as patient advocates.
Shortlisted applicants at Expression of Interest stage will be invited to submit a full application through Breast Cancer Now’s online application system.
If they wish, applicants may, at this stage, ask to be put in touch directly with Pfizer to discuss their proposal and to request further information about the chosen drugs. If more information is available, Pfizer may ask applicants to sign a Confidential Disclosure Agreement before releasing the information.
- All investigators should be based in an academic institution, such as a university, hospital or research institute, located within Europe. Please note that this funding scheme is not intended for industry partners and is for academic researchers only.
- All applications must undertake research using at least one of the Pfizer drugs, either by itself or in combination with other agents.
- In studies that involve teams working at more than one site, one of the investigators must be selected as the Principal Investigator (PI). The PI’s host institution should be the coordinating site for all the financial, regulatory and reporting responsibilities for the grant.
- This funding scheme will support Principal Investigators based in an eligible institution within Europe. However, international collaborators are welcome.
- The leaders of each team involved should be employed by an eligible academic institution. This should be a permanent, open-ended or long-term rolling contract, salaried by the host institution.
- Institutions may be involved in multiple applications, including being the lead site on more than one application. However, each application should be scientifically distinct. Please note that an individual may be the PI on only one application, but may act as a co-investigator on multiple applications.
- Catalyst Programme funding may not be used to cover the same work as that of another current or pending grant.
We will provide a more detailed set of application guidelines to those that are invited to submit a full application for funding under the Catalyst Programme.
Full proposals will be sent to experts in the relevant research area for their comments, before being assessed for funding by the Grants Committee. The Grants Committee will include patient advocates, and the criteria for a successful application will include the likely patient benefit of the research.
The research grants
The research funding will be awarded as a grant from Breast Cancer Now. They will be subject to Breast Cancer Now’s standard Grant Conditions and funding policies, which can be found here. However, they will also be subject to a small number of additional conditions specific to this scheme. These additional conditions will be made available to all those invited to submit a full application.
Providing the drugs
Pfizer will provide the drugs needed for the funded research project only after (i) the grant has been confirmed by Breast Cancer Now; and (ii) conclusion of a separate Materials Transfer Agreement (MTA) (if drugs are to be provided for pre-clinical research only) or Investigator-Initiated Research Agreement (IIR) (if drugs are to be provided for clinical research). The MTA or IIR will be agreed directly between Pfizer and the PI’s host institution. Breast Cancer Now will not be involved in the negotiation of such agreements.
List of Pfizer drugs
List of the drugs and basic information about each (opens as PDF).
Publication and publicity
Both Breast Cancer Now and Pfizer support the freedom of researchers to publish the results from research funded by this programme, even if those results are not favourable to Pfizer. However, researchers will be required to give Pfizer an opportunity to review any proposed publications (including abstracts and posters) before they are submitted in accordance with the procedure shown in the (as applicable) MTA or IIR. This will be solely to identify any results or inventions from the research which could be protected, and to prevent the release of information confidential to Pfizer.
The treatment of the intellectual property associated with the Pfizer drugs and arising from the research funded under the Catalyst Programme will be governed by the terms of the (as applicable) MTA or IIR as agreed between the applicant and Pfizer, not by Breast Cancer Now’s grant conditions.
Deadline for Expressions of Interest through Breast Cancer Now's online grant application system
13 April 2018
Breast Cancer Now provides feedback on the Expressions of Interest and invites full proposals from successful applicants
End of May 2018
Applicants have discussions with Pfizer and obtain further confidential information about the drugs, where necessary
Early June 2018
Deadline for full applications through Breast Cancer Now’s online grant application system
10 August 2018
Grant Committee meets and funding decisions are announced
End of December 2018